Conor McGregor PED Allegations Add New Layer to 2021 Leg Injury Controversy

A new wave of reporting has reignited one of the most controversial injuries in UFC history — Conor McGregor’s catastrophic leg break against Dustin Poirier at UFC 264.

According to a recent report published by The New York Times and covered across multiple MMA outlets, McGregor allegedly used “powerful, banned drugs” during his recovery process following the injury in 2021, raising fresh questions about the circumstances surrounding his rehabilitation and the UFC’s anti-doping landscape.

The claims do not suggest McGregor failed an official drug test during competition. Instead, the report focuses on what allegedly occurred after the injury — during a period when McGregor stepped away from USADA’s testing pool to focus on recovery.

---

The Injury That Changed Everything

McGregor’s leg break occurred in the first round of his trilogy fight against Dustin Poirier at UFC 264 in July 2021.

After a striking exchange, McGregor stepped backward and immediately collapsed, with his tibia and fibula snapping under the pressure. The fight was stopped via doctor’s stoppage, and McGregor was transported out of the Octagon on a stretcher before undergoing surgery shortly after.

The injury required a titanium rod and an extensive rehabilitation process, sidelining the former two-division champion indefinitely.

---

Allegations Around Recovery Protocols

The latest reporting alleges that McGregor’s recovery may have included the use of substances that fall under banned performance-enhancing drug classifications in MMA competition.

Sources cited in the report claim that McGregor’s medical team explored aggressive treatment options for bone regeneration and healing acceleration, which led to discussions around substances typically prohibited under anti-doping rules.

While McGregor’s surgeon, Dr. Neal ElAttrache, did not prescribe banned substances, he reportedly supported efforts to secure a therapeutic use exemption that was ultimately denied.

McGregor’s team has consistently maintained that all recovery decisions were made within medical guidance and in compliance with applicable regulations during his time out of competition.

---

USADA Exit and Anti-Doping Fallout

One of the most scrutinized elements of McGregor’s recovery timeline is his decision to leave the USADA testing pool during rehabilitation.

That move, while permitted under UFC anti-doping rules, effectively removed him from random drug testing while he was not actively competing.

The situation later became part of a broader breakdown between the UFC and USADA, with both sides eventually ending their long-term partnership.

More recently, McGregor accepted an 18-month sanction related to missed drug-testing obligations in 2024, further complicating his regulatory history ahead of a potential return to competition.

---

A Divisive Debate in MMA

The allegations have sparked a familiar debate in combat sports: where is the line between medical recovery and performance enhancement?

Supporters argue that elite-level injuries — particularly a tibia-fibula fracture — often require aggressive treatment protocols to restore function and mobility.

Critics, however, point to the importance of maintaining strict anti-doping standards, even during rehabilitation phases, to preserve competitive integrity.

As one of MMA’s most high-profile athletes, McGregor remains a focal point for both sides of that argument.

---

What Comes Next

McGregor is now reportedly preparing for a long-awaited return to the Octagon in 2026, with high-profile matchup discussions circulating as he re-enters the testing pool and finalizes eligibility requirements.

But the conversation around his 2021 injury is far from closed.

Instead, it continues to shape how fans, fighters, and regulators view the intersection of medical recovery, anti-doping policy, and elite competition in modern MMA.